AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts

Completed · Phase 2

Conditions studied: Autologous Stem Cell Transplantation

In brief

This study evaluates the safety, efficacy, and pharmacokinetics (PK) of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients who would benefit from an autologous stem cell transplant but have failed previous collections or collection attempts with a mobilization regimen of G-CSF alone, chemotherapy and G-CSF, or any other conventional therapy including cytokines, chemotherapy and cytokines and bone marrow harvests. The only change to standard of care of a mobilization regimen that includes G-CSF is the addition of a dose of AMD3100 (plerixafor) on the evening prior to each day of apheresis. Efficacy outcomes include quantification of CD34+ cells in the apheresis product and assessment of successful polymorphonuclear leukocyte (PMN) and platelet (PLT) engraftment after transplantation. PK outcomes include analysis of repeated doses of plerixafor.

Key facts

Study ID: NCT00396331
Run by: Genzyme, a Sanofi Company
People needed: 100
Starts: 2005-10-01
Expected to finish: 2009-12-01
Last updated by the study team: 2014-03-13

Who can join

Age: 18 and older, up to 78. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Eligible to undergo autologous transplantation
Has failed previous collections or collection attempts with a mobilization regimen of granulocyte colony-stimulating factor (G-CSF), chemotherapy and G-CSF or any other conventional therapy including cytokines, chemotherapy and cytokines or bone marrow harvest.
Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1
≥3 weeks since last cycle of chemotherapy (thalidomide, dexamethasone, and Velcade™ are not considered prior chemotherapy for the purpose of this study) NOTE: Although thalidomide, dexamethasone, and Velcade™ are not considered prior chemotherapy for the purpose of this study, none are to be administered within 7 days prior to the first dose of G-CSF (see Exclusion Criteria).
The patient has recovered from all acute toxic effects of prior chemotherapy
White blood cell count (WBC) >2.5*10\^9/L
Absolute neutrophil count >1.5*10\^9/L
Platelet count >85*10\^9/L
Serum creatinine ≤1.5 mg/dl
Creatinine clearance >60 ml/min
Aspartate aminotransferase (AST), alanine transaminase (ALT) and total bilirubin <2x upper limit of normal (ULN)
Left ventricle ejection fraction >45% (by normal echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan)
Forced expiratory volume in one minute (FEV1) >60% of predicted or diffusion lung capacity for carbon monoxide (DLCO) ≥45% of predicted
No active infection of hepatitis B or C
Negative for HIV
Signed informed consent
Women of child-bearing potential agree to use an approved form of contraception

You may not qualify if…

Once 70 patients have enrolled, patients with diagnoses other than lymphoma are not eligible (eg, acute myeloid leukemia, chronic lymphocytic leukemia, or multiple myeloma).
A co-morbid condition which, in the view of the investigators, renders the patient at high risk from treatment complications
A residual acute medical condition resulting from prior chemotherapy
Received Neupogen™, thalidomide, dexamethasone, and/or Velcade™ within 7 days prior to the first dose of G-CSF
Brain metastases or carcinomatous meningitis
Acute infection
Fever (temperature >38°C/100.4°F)
Hypercalcaemia (>1 mg/dL above the ULN)
Positive pregnancy test in female patients
Lactating females
Patients of child-bearing potential unwilling to implement adequate birth control
Patients whose actual body weight exceeds 175% of their ideal body weight
Patients who previously received experimental therapy within 4 weeks of enrolling in this protocol or who are currently enrolled in another experimental protocol during the Mobilization phase

Where it is running

City of Hope National Medical Center' — Duarte, California, United States
H. Lee Moffitt Cancer Center — Tampa, Florida, United States
Blood & Marrow Transplant Group of Georgia — Atlanta, Georgia, United States
University of Mississippi Medical Center, Div of Hematology — Jackson, Mississippi, United States
Kansas City Cancer Centers — Kansas City, Missouri, United States
Hackensack University Medical Center — Hackensack, New Jersey, United States
Virginia Commonwealth University - Massey Cancer Center — Richmond, Virginia, United States
University of Wisconsin, Blood and Bone Marrow Transplant — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.